Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Glia ; 60(3): 422-31, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22161990

RESUMO

Neuroaxonal degeneration is a pathological hallmark of multiple sclerosis (MS) contributing to irreversible neurological disability. Pathological mechanisms leading to axonal damage include autoimmunity to neuronal antigens. In actively demyelinating lesions, myelin is phagocytosed by microglia and blood-borne macrophages, whereas the fate of degenerating or damaged axons is unclear. Phagocytosis is essential for clearing neuronal debris to allow repair and regeneration. However, phagocytosis may lead to antigen presentation and autoimmunity, as has been described for neuroaxonal antigens. Despite this notion, it is unknown whether phagocytosis of neuronal antigens occurs in MS. Here, we show using novel, well-characterized antibodies to axonal antigens, that axonal damage is associated with HLA-DR expressing microglia/macrophages engulfing axonal bulbs, indicative of axonal damage. Neuronal proteins were frequently observed inside HLA-DR(+) cells in areas of axonal damage. In vitro, phagocytosis of neurofilament light (NF-L), present in white and gray matter, was observed in human microglia. The number of NF-L or myelin basic protein (MBP) positive cells was quantified using the mouse macrophage cell line J774.2. Intracellular colocalization of NF-L with the lysosomal membrane protein LAMP1 was observed using confocal microscopy confirming that NF-L is taken up and degraded by the cell. In vivo, NF-L and MBP was observed in cerebrospinal fluid cells from patients with MS, suggesting neuronal debris is drained by this route after axonal damage. In summary, neuroaxonal debris is engulfed, phagocytosed, and degraded by HLA-DR(+) cells. Although uptake is essential for clearing neuronal debris, phagocytic cells could also play a role in augmenting autoimmunity to neuronal antigens.


Assuntos
Microglia/fisiologia , Esclerose Múltipla/patologia , Neurônios/patologia , Fagocitose/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Catepsina D/farmacologia , Catepsinas/farmacologia , Células Cultivadas , Relação Dose-Resposta a Droga , Feminino , Antígenos HLA-DR/metabolismo , Humanos , Masculino , Camundongos , Microglia/efeitos dos fármacos , Microscopia Confocal , Pessoa de Meia-Idade , Esclerose Múltipla/líquido cefalorraquidiano , Proteína Básica da Mielina/líquido cefalorraquidiano , Proteína Básica da Mielina/metabolismo , Fibras Nervosas Mielinizadas/metabolismo , Fibras Nervosas Mielinizadas/patologia , Proteínas de Neurofilamentos/líquido cefalorraquidiano , Proteínas de Neurofilamentos/efeitos dos fármacos , Proteínas de Neurofilamentos/metabolismo , Neurônios/efeitos dos fármacos , Fagocitose/efeitos dos fármacos , Fatores de Tempo
2.
Expert Rev Vaccines ; 9(2): 193-208, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20109029

RESUMO

Periodontitis is a chronic infectious disease that is highly prevalent worldwide and is characterized by inflammation of the gums, and loss of connective tissue and bone support. The Gram-negative anerobic bacterium Porphyromonas gingivalis is generally accepted as the main etiological agent for chronic periodontitis. The objective of this paper is to elucidate the feasibility of achieving protection against periodontitis though immunization against P. gingivalis. Until now, animal studies have showed no complete protection against P. gingivalis. However, current knowledge about P. gingivalis structures could be applicable for further research to develop a successful licensed vaccine and alternative therapeutic strategies. This review reveals that a multicomponent vaccine against P. gingivalis, which includes structures shared among P. gingivalis serotypes, will be feasible to induce broad and complete protection.


Assuntos
Infecções por Bacteroidaceae/prevenção & controle , Infecções por Bacteroidaceae/terapia , Periodontite/prevenção & controle , Periodontite/terapia , Porphyromonas gingivalis/imunologia , Vacinas/imunologia , Vacinas/uso terapêutico , Animais , Humanos , Periodontite/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA